GlassScriptPhysician profile
Eric Zhuang
NPI 1972008605
$1,298.82
in general payments reported to CMS, 2019-2025
15 companies · $559 in 2025
The $559 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $98.64 · 2023: $372 · 2024: $69.90 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $250.00 | 2023 | Brukinsa |
| Lilly USA, LLC | $140.38 | 2023-2025 | Mounjaro |
| Caris Mpi, INC. | $134.91 | 2025 | Mi Cancer Seek |
| Celgene Corporation | $121.82 | 2021 | |
| Amgen INC. | $104.50 | 2025 | Evenity, Prolia, Repatha |
| E.R. Squibb & Sons, L.L.C. | $98.64 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $77.58 | 2021 | |
| Pfizer INC. | $61.22 | 2025 | |
| Sumitomo Pharma America, INC. | $60.95 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $54.57 | 2025 | Airsupra |
| Array Biopharma INC | $47.06 | 2025 | Braftovi, Mektovi, Tukysa |
| Corcept Therapeutics | $46.89 | 2025 | Korlym |
| Abbott Laboratories | $39.82 | 2024 | Piccolo Xpress |
| Exact Sciences Corporation | $30.40 | 2025 | The Cologuard Plus Collection Kit |
| Dexcom, INC. | $30.08 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Zhuang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.